Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells
Open Access
- 23 August 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (8) , e0202827
Abstract
The major drawback of current anti-angiogenic therapies is drug resistance, mainly caused by overexpression of the transcription factor, hypoxia-inducible factor 1α (HIF-1α) as a result of treatment-induced hypoxia, which stimulates cancer cells to develop aggressive and immunosuppressive phenotypes. Moreover, the cancer cell resistance to anti-angiogenic therapies is deeply mediated by the communication between tumor cells and tumor-associated macrophages (TAMs)—the most important microenvironmental cells for the coordination of all supportive processes in tumor development. Thus, simultaneous targeting of TAMs and cancer cells could improve the outcome of the anti-angiogenic therapies. Since our previous studies proved that simvastatin (SIM) exerts strong antiproliferative actions on B16.F10 murine melanoma cells via reduction of TAMs-mediated oxidative stress and inhibition of intratumor production of HIF-1α, we investigated whether the antitumor efficacy of the anti-angiogenic agent—5,6-dimethylxanthenone-4-acetic acid (DMXAA) could be improved by its co-administration with the lipophilic statin. Our results provide confirmatory evidence for the ability of the combined treatment to suppress the aggressive phenotype of the B16.F10 melanoma cells co-cultured with TAMs under hypoxia-mimicking conditions in vitro. Thus, proliferation and migration capacity of the melanoma cells were strongly decelerated after the co-administration of SIM and DMXAA. Moreover, our data suggested that the anti-oxidant action of the combined treatment, as a result of melanogenesis stimulation, might be the principal cause for the simultaneous suppression of key molecules involved in melanoma cell aggressiveness, present in melanoma cells (HIF-1α) as well as in TAMs (arginase-1). Finally, the concomitant suppression of these proteins might have contributed to a very strong inhibition of the angiogenic capacity of the cell co-culture microenvironment.Keywords
Funding Information
- Romanian Ministry of Education, Research and Innovation CNCS-UEFISCDI (Grant PN-II-RU-TE-2014–4–1191 (No. 235/ 2015) within PNCDI II)
- Romanian Ministry of Research and Innovation, CNCS-UEFISCDI (PN-III-P4-ID-PCE-2016-0342 (contract no. 91/2017) within PNCDI III)
This publication has 53 references indexed in Scilit:
- The mechanisms by which polyamines accelerate tumor spreadJournal of Experimental & Clinical Cancer Research, 2011
- Hypoxia-Induced Angiogenesis: Good and EvilGenes & Cancer, 2011
- IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competenceLaboratory Investigation, 2011
- The Isolation and Characterization of Murine MacrophagesCurrent Protocols in Immunology, 2008
- Interleukin-10 Promotes Pathological Angiogenesis by Regulating Macrophage Response to Hypoxia during DevelopmentPLOS ONE, 2008
- Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectivesImmunological Reviews, 2008
- In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitroNature Protocols, 2007
- Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cellsCancer Cell International, 2007
- Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapyEuropean Journal of Cancer, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001